Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab for Prevention of Acute Humoral Rejection in Kidney Transplantation
NCT01106027Phase 2
Key facts
- Status
- Terminated
- Start
- Mar 2010
- Primary completion
- Aug 2016
- Countries
- 1
- Sponsor
- Mayo Clinic
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Drugs
- eculizumab
- Conditions
- kidney transplant rejection
01
Overview
Phase 2, open-label, single-arm trial of eculizumab in kidney transplant rejection, sponsored by Mayo Clinic. Primary endpoint: Number of Subjects With Acute Humoral Rejection (AHR) at 1 year. Started Mar 2010; status: terminated.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Eculizumab
Eculizumab added to standard posttransplant care
03
Endpoints
Primary
Number of Subjects With Acute Humoral Rejection (AHR)
Beyond the preview
Go deeper on NCT01106027.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01106027.